Watching Keros Therapeutics, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planKeros Therapeutics, Inc.
kerostx.comAI Executive Summary
AI-powered analysis of 8-K filing content
Keros Therapeutics announced the voluntary resignation of CFO Keith Regnante effective August 3, 2026, and appointed Annita Tanini, the Corporate Controller and Vice President of Finance, as interim principal financial officer effective August 4, 2026. The departure was amicable with no accounting or financial reporting disagreements, indicating a smooth leadership transition.
Key Takeaways
Keith Regnante resigned voluntarily as CFO to pursue other opportunities, with departure effective August 3, 2026
Annita Tanini, previously Corporate Controller and Vice President of Finance, appointed as interim principal financial officer and principal accounting officer effective August 4, 2026
2 more takeaways
Filing Overview
What This Means
Keros Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.